Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2007 Nov;64(5):578-9.
doi: 10.1111/j.1365-2125.2007.02973.x. Epub 2007 Aug 31.

Commentary on Dartois et al.--model building in population PK-PD analyses. A 2002-2004 literature survey

Affiliations
Comment

Commentary on Dartois et al.--model building in population PK-PD analyses. A 2002-2004 literature survey

Goonaseelan Pillai et al. Br J Clin Pharmacol. 2007 Nov.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

References

    1. Dartois C, Brendel K, Comets E, Laffont C, Laveille C, Tranchand B, Mentre F, Lemenuel A, Girard P. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey. Br J Clin Pharmacol. 2007 Epub ahead of print. doi: 10.1111/j1365-2125.2007.02975.x. - DOI - PMC - PubMed
    1. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated?: a survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46:221–34. - PMC - PubMed
    1. Retout S, Mentré F. Optimisation of individual and population designs using Splus. J Pharmacokinet Pharmacodyn. 2003;30:417–43. - PubMed
    1. Duffull SB, Mentre F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res. 2001;18:83–9. - PubMed
    1. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol. 2000;40:67–95. - PubMed